2026 Interim Report
Filed with HKEX · Stock code 2565 · · 62 pages · English
Summary by 6ix AI
The report highlights the progress of its core product, Visepegenatide injection, including a strategic cooperation agreement for its commercialization in the Chinese mainland. Financially, the company reported losses from operations and for the period, reflecting ongoing investments in research and development. The management discussion emphasizes the company's focus on innovative therapies for metabolic diseases and the integration of advanced R&D capabilities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from PegBio
- Change in use of proceeds from the global offering
- Proposed change of auditor
- Voluntary announcement core product Visepegenatide injection passed the preliminary review in accordance with the 2026 national reimbursement drug list adjustment
- Next Day Disclosure Return
- List of directors and their roles and functions
Later from PegBio
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- (1) Proposed removal of auditor (2) proposed appointment of auditor (3) proposed change in use of proceeds from the global offering and (4) notice of the 2026 first extraordinary general meeting
- Notice of the 2026 first extraordinary general meeting
- Form of proxy for use at the 2026 first extraordinary general meeting to be held on Thursday, November 12, 2026
- Placing of new h shares under general mandate
Follow PegBio into a list and get an email when it puts out news.
Follow PegBio